摘要
目的:对比不同剂量米非司酮对子宫内膜异位症疗效。方法:选择92例子宫内膜异位症患者随机分为两组,每组46例。两组患者入组后均由同一组具5年以上临床经验的医护人员进行治疗,在月经周期第1d对照组给予口服米非司酮片,每次10mg,每天1次,观察组给药剂量为每次5mg,每天1次,连续6个月。对比两组患者疗效、子宫动脉血流动力学指标及不良反应发生情况。结果:观察组有效率为95.65%,与对照组的91.30%差异无统计学意义(P>0.05)。治疗前后两组患者两侧子宫动脉最大血流速度均明显升高,两侧子宫动脉搏动指数与阻力指数均明显下降(P<0.05),但治疗后两组患者各血流动力学指标对比差异均无统计学意义(P>0.05)。观察组不良反应总发生率为17.39%,明显低于对照组的32.61%(P<0.05)。结论:米非司酮治疗子宫内膜异位症时不同剂量疗效及对患者子宫血流动力学参数的影响均无显著差异,但低剂量组不良反应发生率明显降低。
Objective: To compare the effects of different doses of mifepristone on endometriosis. Method: 92 cases of endometriosis were randomly divided into two groups, 46 cases in each group. Two groups of patients were treated by the same group of doctors and nurses with more than 5 years of clinical experience. On the first day of menstrual cycle, the control group was given oral mifepristone tablets, 10 mg each time, once a day. The dosage of the observation group was 5 mg each time, once a day for 6 months. The curative effect, uterine artery hemodynamics and adverse reactions were compared between the two groups. Result: There was no significant difference in treatment effectiveness between the two groups(95.65% vs 91.30%)(P>0.05). Before and after treatment, the maximum blood flow velocity of uterine artery increased significantly in both groups, and the pulsation index and resistance index of uterine artery decreased significantly in both groups(P<0.05), but there was no significant difference in the hemodynamic indexes between the two groups after treatment(P>0.05). The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(17.39% vs 32.61%)(P<0.05). Conclusion: There was no significant difference in the efficacy of different doses of mifepristone in the treatment of endometriosis and its effect on uterine hemodynamic parameters, but the incidence of adverse reactions in the low dose group was significantly reduced.
作者
魏巧芳
WEI Qiao-fang(Department of Obstetrics and Gynecology,Wugang People’s Hospital,Pingdingshan Henan 462500,China)
出处
《药品评价》
CAS
2019年第20期28-29,共2页
Drug Evaluation
